Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology

Research Conducted under Existing $9.4 Million NIAID Thermostability Grant
PRINCETON, N.J., Feb. 6, 2012 /PRNewswire via COMTEX/ — Soligenix, Inc. /quotes/zigman/8581341 SNGXD -1.39% (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions. Read more of this entry

About these ads